Ocugen to Host Conference Call on Friday, August 14 at 8:30 a.m. ET to Discuss Second Quarter 2020 Financial Results and Provide Business Update
Ocugen, Inc. (NASDAQ: OCGN) announced it will host a conference call on August 14, 2020, at 8:30 a.m. to discuss its Q2 2020 financial results and provide a business update. The company will release earnings pre-market the same day. Investors can participate via phone or webcast, accessible on the Ocugen website. The firm focuses on developing therapies for blindness diseases, leveraging a modifier gene therapy platform aimed at treating multiple retinal conditions with a single drug.
- Ocugen's modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug.
- None.
MALVERN, Pa., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced that it will host a conference call to discuss its Q2 2020 financial results and provide a business update at 8:30 a.m. on Friday, August 14, 2020.
The company will issue a pre-market earnings announcement the same day. Investors are invited to participate on the call using the following details:
| Dial-In Number: | (844) 873-7330 (U.S.) or (602) 563-8473 (international) | |
| Conference ID: | ID 5587104 | |
| Webcast: | Available in the “Investors” section of the Ocugen website at https://ir.ocugen.com/ and archived for approximately 45 days following the call |
About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, please visit https://ocugen.com/.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.
Corporate Contact:
Ocugen, Inc.
Sanjay Subramanian
Chief Financial Officer
IR@Ocugen.com
Media Contact:
LaVoieHealthScience
Emmie Twombly
etwombly@lavoiehealthscience.com
+1 857-389-6042
FAQ
When is Ocugen's Q2 2020 earnings call?
How can I participate in Ocugen's earnings call?
What are Ocugen's main areas of focus?
What is the significance of Ocugen's modifier gene therapy platform?
